Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives

Neoadjuvant endocrine treatment (NET) associates to satisfactory rates of breast conservative surgery and conversions from inoperable to operable hormone receptor-positive (HR+)/HER2-negative breast cancer (BC), with less toxicities than neoadjuvant chemotherapy (NACT) and similar outcomes. Hence, i...

Descripción completa

Detalles Bibliográficos
Autores: Sirico, Marianna, Virga, Alessandra, Conte, Benedetta, Urbini, Milena, Ulivi, Paola, Gianni, Caterina, Merloni, Filippo, Palleschi, Michela, Gasperoni, Marco, Curcio, Annalisa, Saha, Debjani, Buono, Giuseppe, Muñoz, Montserrat, De Giorgi, Ugo, Schettini, Francesco
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/214184
Acceso en línea:https://hdl.handle.net/2445/214184
Access Level:acceso abierto
Palabra clave:Càncer de mama
Marcadors bioquímics
Endocrinologia
Tractament adjuvant del càncer
Breast cancer
Biochemical markers
Endocrinology
Adjuvant treatment of cancer
Descripción
Sumario:Neoadjuvant endocrine treatment (NET) associates to satisfactory rates of breast conservative surgery and conversions from inoperable to operable hormone receptor-positive (HR+)/HER2-negative breast cancer (BC), with less toxicities than neoadjuvant chemotherapy (NACT) and similar outcomes. Hence, it has been proposed as a logical alternative to NACT in patients with HR+/HER2- BC candidate to a neoadjuvant approach. Nevertheless, potential barriers to the widespread use of NET include the heterogeneous nature of patient response coupled with the long duration needed to achieve a clinical response. However, interest in NET has significantly increased in the last decade, owing to more in-depth investigation of several biomarkers for a more adequate patient selection and on-treatment benefit monitoring, such as PEPI score, Ki67 and genomic assays. This review is intended to describe the state-of-the-art regarding NET, its future perspectives and potential integration with molecular biomarkers for the optimal selection of patients, regimen and duration of (neo)adjuvant treatments.

Similares en LA Referencia